机器学习评分系统预测难治性类风湿关节炎进展:来自FIRST登记研究
本研究基于FIRST多中心登记中1221例首次启用b/tsDMARD的类风湿关节炎患者,用43项基线特征构建25个预测模型,筛选出Lasso逻辑回归模型(AUC 0.71),并据此设计评分系统预测D2T RA进展;评分系统识别的高风险患者中,IL-6Ri显著降低D2T RA进展(RR 0.48)。
要点
- 1221例中193例(15.8%)在中位54.0个月进展为D2T RA。
- 疼痛评分、血沉和合并肺病是D2T RA的关键预测因素。
- 评分系统识别的高风险患者中,IL-6Ri显著降低D2T RA进展(RR 0.48)。
核心结论
- 研究开发并验证了预测D2T RA进展的评分系统,可识别高风险患者并提示IL-6Ri的优势。
研究设计与样本
- 基于FIRST多中心协作登记中1221例首次启用b/tsDMARD的类风湿关节炎患者,用43项基线特征构建25个预测模型并测试性能。
- 基于所选模型设计评分系统并进行内部验证。
主要发现
- 1221例中193例(15.8%)在中位54.0个月后进展为D2T RA。
- 进展者压痛关节数、总体评估、疼痛评分、HAQ评分和CDAI评分更高,合并肺病更常见。
- Lasso逻辑回归模型表现最佳(AUC 0.71),识别疼痛评分、血沉和合并肺病为关键预测因素。
- 基于上述预测因素的评分系统表现与模型相当。
- 评分系统识别的高风险患者中,IL-6Ri显著降低D2T RA进展(RR 0.48)。
关键数值与推荐
- D2T RA进展率:193/1221(15.8%),中位进展时间54.0个月。
- 最佳模型Lasso逻辑回归的AUC为0.71。
- 高风险患者中IL-6Ri降低D2T RA进展的相对风险(RR)为0.48。
临床怎么用
- 可使用基于疼痛评分、血沉和合并肺病的评分系统识别D2T RA高风险患者。
- 对评分系统识别的高风险患者,可考虑优先选用IL-6Ri以降低D2T RA进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to develop and validate a prediction model for the future progression of difficult-to-treat rheumatoid arthritis (D2T RA) and support the precise use of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). METHODS: Data were analysed from 1221 patients with rheumatoid arthritis in the FIRST registry, a multicentre collaborative database, who initiated their first b/tsDMARD. 25 prediction models for D2T RA were generated using 43 baseline characteristics prior to initiating the first b/tsDMARD. Model performances were tested. A scoring system based on the selected model was designed and internally validated for use in routine clinical practice. RESULTS: Among the 1221 patients, 193 (15.8%) progressed to D2T RA after a median of 54.0 months. These patients had higher tender joint count, global assessment, pain scale, Health Assessment Questionnaire score and Clinical Disease Activity Index score and more frequent coexisting lung disease. Among the machine learning models tested, Lasso logistic regression performed best (area under the curve 0.71), identifying pain scale, erythrocyte sedimentation rate and coexisting lung disease as key predictors. The scoring system based on these predictors demonstrated comparable performance. Among patients identified as high risk for D2T RA by the scoring system, interleukin-6 receptor inhibitors (IL-6Ri) significantly reduced D2T RA progression (relative risk (RR): 0.48). CONCLUSION: This study developed and validated a scoring system to predict D2T RA progression and identify patients at high risk and suggested the advantages of IL-6Ri. This system may advance precision medicine in RA and may contribute to controlling unmet needs.
引用
- Ueno M, Sonomoto K, Tanaka H, et al. Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry. RMD Open. 2026. PMID: 41545312. doi:10.1136/rmdopen-2025-006544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。